Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (261-270 of 566) with videos related to

Pageof 57
Sort By:
American Journal of Hematology|August 24, 2010
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myelomaKristen Detweiler-Short, Suzanne Hayman, Morie A Gertz, et al.
Blood Cancer Journal|February 28, 2019
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)Charalampia Kyriakou, Sean Molloy, Frank Vrionis, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 6, 2023
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 StudySara Bringhen, Luděk Pour, Reuben Benjamin, et al.
American Journal of Hematology|September 28, 2010
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugsAngela Dispenzieri, David Dingli, Shaji K Kumar, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosisS Vincent Rajkumar, Ruben A Mesa, Rafael Fonseca, et al.
Blood Advances|March 22, 2022
Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening methodCeline M Vachon, Josiah Murray, Cristine Allmer, et al.
Blood|September 25, 2024
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysisRahul Banerjee, Rachael Sexton, Andrew J Cowan, et al.
Mayo Clinic Proceedings|January 17, 2003
Review of 1027 patients with newly diagnosed multiple myelomaRobert A Kyle, Morie A Gertz, Thomas E Witzig, et al.
Blood Cancer Journal|January 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myelomaWee-Joo Chng, Sagar Lonial, Gareth J Morgan, et al.
Pageof 57

Showing results (261-270 of 566) with videos related to

Sort By:
Pageof 57
American Journal of Hematology|August 24, 2010
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myelomaKristen Detweiler-Short, Suzanne Hayman, Morie A Gertz, et al.
Blood Cancer Journal|February 28, 2019
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)Charalampia Kyriakou, Sean Molloy, Frank Vrionis, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 6, 2023
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 StudySara Bringhen, Luděk Pour, Reuben Benjamin, et al.
American Journal of Hematology|September 28, 2010
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugsAngela Dispenzieri, David Dingli, Shaji K Kumar, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosisS Vincent Rajkumar, Ruben A Mesa, Rafael Fonseca, et al.
Blood Advances|March 22, 2022
Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening methodCeline M Vachon, Josiah Murray, Cristine Allmer, et al.
Blood|September 25, 2024
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysisRahul Banerjee, Rachael Sexton, Andrew J Cowan, et al.
Mayo Clinic Proceedings|January 17, 2003
Review of 1027 patients with newly diagnosed multiple myelomaRobert A Kyle, Morie A Gertz, Thomas E Witzig, et al.
Blood Cancer Journal|January 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myelomaWee-Joo Chng, Sagar Lonial, Gareth J Morgan, et al.
Pageof 57